Mirae Asset Global Investments Co. Ltd. Sells 100,885 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Mirae Asset Global Investments Co. Ltd. lowered its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 35.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 185,858 shares of the company’s stock after selling 100,885 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Intellia Therapeutics were worth $5,667,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. ARK Investment Management LLC grew its stake in shares of Intellia Therapeutics by 14.7% in the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after buying an additional 1,463,820 shares during the last quarter. BlackRock Inc. grew its stake in shares of Intellia Therapeutics by 9.6% in the 2nd quarter. BlackRock Inc. now owns 8,054,963 shares of the company’s stock worth $328,481,000 after buying an additional 706,344 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Intellia Therapeutics by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 6,617,323 shares of the company’s stock worth $370,305,000 after buying an additional 108,041 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Intellia Therapeutics by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,520,295 shares of the company’s stock worth $111,312,000 after buying an additional 125,639 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Intellia Therapeutics by 31.1% in the 2nd quarter. State Street Corp now owns 3,143,811 shares of the company’s stock worth $162,724,000 after buying an additional 746,284 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Transactions at Intellia Therapeutics

In other news, EVP James Basta sold 2,297 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the sale, the executive vice president now directly owns 81,571 shares in the company, valued at approximately $2,691,027.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.00% of the stock is currently owned by company insiders.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $24.27 on Monday. The business’s fifty day moving average price is $27.69 and its 200-day moving average price is $28.17. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -4.49 and a beta of 1.77. Intellia Therapeutics, Inc. has a 1-year low of $22.67 and a 1-year high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.01. The firm had revenue of ($1.92) million during the quarter, compared to analyst estimates of $15.10 million. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. During the same period in the prior year, the business posted ($1.40) EPS. Equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on NTLA shares. Wedbush restated a “neutral” rating and issued a $29.00 price target on shares of Intellia Therapeutics in a research note on Thursday, February 15th. Wolfe Research initiated coverage on Intellia Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Canaccord Genuity Group upped their price objective on Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Finally, The Goldman Sachs Group cut Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $136.00 to $32.00 in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.